US court delays launch of country's first biosimilar
This article was originally published in SRA
Executive Summary
The first biosimilar may have been approved in the US but its launch is being delayed. Amgen has won its motion for an injunction to stop Novartis and its Sandoz unit from launching Zarxio (filgrastim-sndz) – referenced on Amgen's human granulocyte colony-stimulating factor, Neupogen (filgrastim) – until the US Court of Appeals for the Federal Circuit renders a decision in an ongoing lawsuit.